Assessment of Humoral Immunity to Measles Virus in Cancer Survivor Children after Chemotherapy: A Case-Control Study

• Published in: Fetal and pediatric pathology Vol. 41; no. 5; pp. 711 - 721
• Main Authors: Abdelaziz, Tarek A., Atfy, Mervat, Risha, Amr I., Gohary, Mahmoud M., Baz, Eman Gamal
• Format: Journal Article
• Language: English
• Published: 03.09.2022
• ISSN: 1551-3815; 1551-3823
• DOI: 10.1080/15513815.2021.1953653

This case-control study was conducted to determine the antibody titer against the measles virus in childhood cancer survivors' post-chemotherapy treatment to determine the patient's immune status against the measles virus. We enrolled 38 children who were in complete remission and whose treatments had been stopped for at least 3 months and 38 age and sex-matched healthy controls. We analyzed the medical records of the cancer survivors, and each study participant's serum sample was analyzed by the ELISA method to determine the antibody titer against measles. The cancer survivors had significantly lower measles antibody titers than the healthy control participants, and 78.9% of cancer survivors were unprotected (seronegative) compared to 7.9% in healthy controls. After multivariate analysis, there was no statistically significant factor associated with loss of protective humoral immunity against measles. These results underline the need for post-chemotherapy measles antibody testing and revaccination of seronegative survivors.